<DOC>
	<DOCNO>NCT02898922</DOCNO>
	<brief_summary>Background Hepatitis B virus ( HBV ) co-infection individual hepatitis C virus ( HCV ) enhance severity hepatitis risk liver cirrhosis hepatocellular carcinoma ( HCC ) . Hepatitis B vaccine effective measure prevent HBV infection . Whether patient HCV infection non-protective antibody responses hepatitis B vaccination frequently healthy subject still controversial study cytokine response seldom report . Methods Not-in-treatment patient chronic HCV infection 1:2 community/gender match healthy control obtain community-based screening . All participant receive three dos hepatitis B vaccine ( 20 μg HBsAg/ml/dose ) 0 , 1 6 month schedule . Anti-HBs test 1 month third dose vaccination compare two group . Spot-forming cell ( SFCs ) interferon-γ ( IFN-γ ) , interleukin-2 ( IL-2 ) , interleukin-4 ( IL-4 ) , interleukin-5 ( IL-5 ) interleukin-6 ( IL-6 ) produce lymphocyte test enzyme-linked immunospot ( ELISPOT ) compare two group .</brief_summary>
	<brief_title>Robust Antibody Cytokine Response Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study China</brief_title>
	<detailed_description>Study design participants The study conduct three county ( Yucheng , Xintai Dongchangfu ) Shandong province , China , high report HCV case number province . Potential patient chronic HCV infection recruit check medical record hospital inquire village doctor . Healthy individual randomly select 3 5 time potential patient HCV infection county . Questionnaire investigation make blood sample collect potential patient healthy individual way . Questionnaire survey We perform questionnaire-based survey collect base line information participant , include demographic information ( age , sex , height weight ) , medical history ( allergy , diagnosis treatment chronic hepatitis C , vaccination , fever , acute disease ) , behavioral status ( smoking , drinking , pregnancy lactation ) . Hepatitis B vaccination follow-up Three dose hepatitis B vaccine make Recombinant DNA Techniques Saccharomyces Cerevisiae ( 20 μg HBsAg/1.0ml per dose , Shenzhen Kangtai Biological Products Co. , Ltd. , Shenzhen , Guangdong Province , China ) give intramuscularly deltoid region participant 0 , 1 6 month respectively . Blood sample participant collect one month first third dose vaccination . Laboratory assay physical examination Screening test physical examination HBsAg , anti-HBs , HBeAg , anti-HBe , anti-HBc , anti-HCV HCV RNA assay subject inclusion visit ; serum bilirubin , serum albumin , prothrombin time , plasma ALT aspartate aminotransferase ( AST ) detect HCV group . HBsAg , anti-HBs , HBeAg , anti-HBe anti-HBc assay Abbott Chemiluminesent Microparticle ImmunoAssay ( CMIA ) ( Abbott Ireland Diagnostics Division , Sligo , Ireland ) . Anti-HCV measured ELISA commercial kit ( Intec product , INC , Xiamen , China ) . HCV RNA measure Quantitative Real-time PCR commercially available kit ( QIAGEN , Shenzhen , China ) . Serum bilirubin , albumin , prothrombin time , plasma ALT AST measure use standard reagent method . In order assess disease activity , patient HCV infection receive clinical examination , include interrogation , physical examination ultrasonography . Anti-HBs assay vaccination Anti-HBs detect use CMIA ( Abbott Ireland Diagnostics Division , Sligo , Ireland ) one month first third dose vaccination . Although without serological HBV marker , subject define history HBV infection hepatitis B vaccination anti-HBs ≥100 mIU/ml one month first dose vaccination . CMI assay Before first dose vaccination one month third dose vaccination , 43 subject HCV group 37 subject healthy control group select randomly isolated peripheral blood mononuclear cell ( PBMCs ) test CMI function respectively , include interferon-γ ( IFN-γ ) , interleukin-2 ( IL-2 ) , interleukin-4 ( IL-4 ) , interleukin-5 ( IL-5 ) interleukin-6 ( IL-6 ) . S28-39 polypeptide , MHC class I polypeptide , MHC class II polypeptide HBsAg use cell immunologic stimulant IFN-γ respectively . Hepatitis B virus surface antigen use cell immunologic stimulant IL-2 , IL-4 , IL-5 IL-6 . S28-39 polypeptide ，MHC class I polypeptide mixture MHC class II polypeptide mixture synthetized BO MAI JIE Technology Co. LTD. ( Beijing , China ) . HBsAg supply Shenzhen Kangtai Biological Products Co. , Ltd. ( Shenzhen , China ) . PBMCs separate EDTA-anticoagulated blood adjust concentration 2 × 106 cell /mL . 100 μL 2 × 106 cell /mL PBMCs add pre-coated PVDF 96-well plate 100 μL HBsAg S28-39 peptide ( IPQSLDSWWTSL , final concentration : 10 μg/mL ) , 100 μL MHC class I polypeptide mixture , 100 μL MHC class II polypeptide mixture 100 μL HBsAg ( 80μg/mL ) well . When come IL-2 , IL-4 , IL-5 IL-6 , plat flood 100 μL 2 × 106 cell /mL PBMC 100 μL HBsAg ( 80μg/mL ) well . Then incubate 37 °C , 5 % CO2 humidify incubator 20 h ( IFN-γ , IL-2 ) 40 h ( IL-4 , IL-5 IL-6 ) . After incubation plate manipulate accord R &amp; D ELISPOT Kit ( R &amp; D Systems , Inc. ) Instruction Manual . Spot-forming Cells ( SFCs ) enumerate ImmunoSpotTM system ( Cellular Technology Ltd. ) . Safety assessment Participants provide diary card record occurrence severity solicit local reaction injection site ( pain , induration , erythema , edema , pruritus ) 7 day vaccination , solicit systemic reaction ( fever , headache , fatigue , cough , myalgia , asthenia , vertigo , diarrhea ) , unsolicited adverse 29 day vaccination . Statistical analysis Data entry database management perform EPIDATA 3.0 Microsoft excel 2010 respectively . Data analysis perform Stata 11.0 . Differences HCV group healthy control group continuous categorical variable examine use condition logistic regression . Subgroups non- low-responders versus normal- high-responders evaluate relation demography characteristic , biochemical indicator , liver disease statue HCV RNA . A Student 's test one-way ANOVA use compare average anti-HBs titer different subgroup . Fisher 's exact test use compare response rate . Nonparametric test use compare immunodotting spot . Sperman rank correlation analysis use evaluate correlation immunodotting spots anti-HBs . For comparison , two-side P &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion HCV group follow : ( 1 ) age ≥ 22 year Han nationality ; ( 2 ) history hepatitis B vaccination ; ( 3 ) notintreatment patient antiHCV HCV RNA positive ; ( 4 ) diagnosis chronic hepatitis C basis selfreported history HCV infection ( 6 month ) screen test inclusion ; ( 5 ) negative HBsAg , antiHBs , hepatitis B e antigen ( HBeAg ) , antibody hepatitis B e antigen ( antiHBe ) antibody hepatitis B core antigen ( antiHBc ) . Inclusion criterion healthy control group follow : ( 1 ) age ≥ 22 year Han nationality ; ( 2 ) history hepatitis B vaccination ; ( 3 ) negative antiHCV HCV RNA ; ( 4 ) negative HBsAg , antiHBs , HBeAg , antiHBe antiHBc ; ( 5 ) selfreported acute chronic disease . ( 1 ) allergy vaccine component ; ( 2 ) pregnancy lactation ; ( 3 ) axillary temperature ≥38℃ past three day , acute disease past seven day vaccination history vaccine past four week ; ( 4 ) suffering disease may influence immune function , severe cirrhosis ChildPugh score &gt; 5 , renal failure , bleed diathesis , malignant tumor HIV infection ; ( 5 ) receive take antiviral treatment ; ( 6 ) chronic liver diseases except cause HCV .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>